BMO Capital analyst Matthew Luchini lowered his price target on Spark Therapeutics to $48 after its Q3 earnings miss, stating that the weakness in its shares also reflects continued uncertainty on the outlook for SPK-8011 for hemophilia A. The analyst also points to the company's "lack of catalysts", stating that the announcement that "FVIII levels from key highest dose cohort will not be available until MY19, rather than at ASH, pushes out a key dataset that could potentially get the program back on track". With Spark Therapeutics' Luxturna results also suggesting "slow but steady growth", Luchini keeps his Market Perform rating on the stock based on its limited near-term upside.